Altimmune, Inc. Common Stock and Tao Synergies Inc. Common Stock
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Open ALT dashboard ↗TAO Synergies Inc. owns and operates an AI token. The company executes a cryptocurrency treasury strategy centered on the acquisition and staking of the TAO token, the native utility token of the Bittensor network. TAO Synergies Inc. was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York.
Open TAOX dashboard ↗You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.
Sign in →